Get started
Author

Heleen Vellekoop

Observed names: H Vellekoop, H. Vellekoop, Vellekoop, Heleen
ORCID: 0000-0001-5127-240X
Observed ORCID: 0000-0001-5127-240X
OpenAlex ID: A5086441869
Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options
2022 · Rositsa Koleva-Kolarova, James Buchanan, et al. · Applied Health Economics and Health Policy · 65
PDF
The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis
2022 · Heleen Vellekoop, Matthijs Versteegh, et al. · Value in Health · 49
PDF
Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine
2021 · Heleen Vellekoop, Simone Huygens, et al. · PharmacoEconomics · 45
PDF
Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib
2022 · Simone Huygens, Heleen Vellekoop, et al. · Value in Health · 15
PDF
Supporting a review of the benefits package of the National Health Insurance Scheme in Ghana
2022 · Heleen Vellekoop, Emmanuel Odame, et al. · Cost Effectiveness and Resource Allocation · 13
PDF
Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation
2023 · Rositsa Koleva-Kolarova, László Szilberhorn, et al. · Personalized Medicine · 11
PDF
Cost–effectiveness of Genetic-Based Screening Strategies for Maturity-Onset Diabetes of the Young
2023 · Gábor Kovács, Dávid Nagy, et al. · Personalized Medicine · 7
105P Prognostic value of the NTRK fusion biomarker in the Netherlands
2021 · I. Santi, H. Vellekoop, et al. · Annals of Oncology · 7
Budget Impact and Transferability of Cost–effectiveness of DPYD Testing in Metastatic Breast Cancer in Three Health Systems
2023 · Rositsa Koleva-Kolarova, Heleen Vellekoop, et al. · Personalized Medicine · 6
Cost–effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK
2023 · Rositsa Koleva-Kolarova, Heleen Vellekoop, et al. · Personalized Medicine · 6
Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands
2024 · Irene Santi, Heleen Vellekoop, et al. · Molecular Diagnosis & Therapy · 5
PDF
Cost–effectiveness of Alternative NTRK Testing Strategies in Cancer Patients Followed by Histology-Independent Therapy with Entrectinib: an Analysis of Three European Countries
2023 · Heleen Vellekoop, Simone Huygens, et al. · Personalized Medicine · 5
Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries
2023 · László Szilberhorn, Tamás Zelei, et al. · Personalized Medicine · 3
Lessons Learned from the Application of the HEcoPerMed Guidance to Three Modeling Case Studies
2023 · Balázs Nagy, Tamás Zelei, et al. · Personalized Medicine · 3
PDF
Position Paper: Personalised Medicine from a Health Economic Perspective - Lessons Learned and Potential Opportunities Ahead
2022 · Rutten-van Molken, Maureen, Versteegh, Matthijs, et al. · Zenodo (CERN European Organization for Nuclear Research)
POSB75 What Is the Net Added Value of Personalised Medicine? A Systematic Literature Review
2022 · H Vellekoop, S Huygens, et al. · Value in Health
Waardebepaling, implementatie en bekostiging van voorspellende testen in Nederland
2019 · Gimon De Graaf, De Groot, Saskia, et al. · EUR Research Repository (Erasmus University Rotterdam)
Works count: 25
Citation count: 240
H-index: 7
I10-index: 6
Year
Topic
Type